• Cryptocurrencies
  • Voorspellingsmarkten
  • Nieuws
  • Agentisch Handelen
  • Artikelen
  • Competities

Zoeken Cryptocurrencies

Trends Cryptocurrencies

CoinRithm

Bedrijf

Rechtspersoon
Bees-x Limited
Bedrijfsnummer
13308136
Opgericht in
England and Wales
Statutaire zetel
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is een informatie- en onderzoeksdienst van Bees-x Limited. Het is niet door de Financial Conduct Authority (FCA) gemachtigd om gereguleerde activiteiten uit te voeren, en niets op deze site vormt financieel advies.

Ontdekken

CryptocurrenciesVoorspellingsmarktenNieuwsArtikelenAgent ArenaCompetities

Functies

DashboardNephandelAgentisch HandelenPortefeuilleVolglijstInstellingen

Bedrijf

Over OnsMethodologieGebruiks- voorwaardenPrivacybeleidCookiebeleidVrijwaring

Ondersteuning

KlantenserviceFAQOntwikkelaarskitMCP-documentatie

Sociale Media

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Rechten voorbehouden.
Verkrijgbaar via Google PlayDownloaden in de App Store
  • Home
  • MarktenVoorspellingsmarkten
  • Nieuws
  • Dashboard
  1. Voorspellingsmarkten
  2. Health & Medicine
  3. When will Intellia Therapeutics submit a BLA for Lonvo-z?
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

Health & MedicineOne-OffWetenschap2mnd
KalshiKalshiBeschikbaarheid controlerenKYC vereist2% kosten
Huidige impliciete kans
before September
before September 45%
Koploper van 6 uitkomsten
Marktkwaliteit

24 / 100

Lage kwaliteit
24u volume

€ 0

Liquiditeit

€ 20,7

Lage liquiditeit
Bied / Laat

35.0% / 45.0%

Spread

28.6%

Brede spread
Marktdata

Bijgewerkt 4 minuten geleden

24 mrt 26, 14:001 sep 26, 14:00

Trends

Uitkomst24uKans

Gekozen uitkomst

before September45%

Regels

If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.

Kalshi
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.

Gerelateerde Markten

When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

€ 4,6
before April 2027: 72%KalshiKALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

€ 0,3
before September: 31%KalshiKALSHI
Will there be a year without polio before 2030?

Will there be a year without polio before 2030?

€ 0
Ja: 10%KalshiKALSHI
Which countries will have an Ebola case in 2026?

Which countries will have an Ebola case in 2026?

€ 138,2
Uganda: 100%PolymarketPOLYMARKET
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

€ 147,6K
Ja: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

€ 16,6K
Ja: 10%PolymarketPOLYMARKET

Actief in deze onderwerpen

BitcoinBTC$62,835.25+1.92%EthereumETH$1,657.81+1.25%SolanaSOL$65.23+1.59%DogecoinDOGE$0.0851+1.38%XRPXRP$1.12+0.44%BNBBNB$601.79+2.49%

Gerelateerd Nieuws

Anthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.NewsChainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsQuantus’ Q-Day Brings Together Leading Cryptographers, Blockchain Builders, Investors, and Researchers to Prepare for the Post-Quantum FutureBlockchain ReporterOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News

Regels

If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.

Kalshi
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.